Stock 603707 NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
13.24 CNY +0.46% Intraday chart for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. +8.70% -11.73%
06:08am Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 16 King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection
MT
NKFPharma Gets Certificate to Register Voriconazole for Injection
MT
Nanjing King-Friend’s Cancer Drug Get US FDA Nod
MT
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection
MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S
CI
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US
MT
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection
MT
NKFPharma Unit Gets US FDA Nod for Cancer Drug
MT
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US
MT
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide
MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
NKFPharma Gets Certification for Lung Cancer Drug
MT
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation
MT
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market
MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Chimigen Bio announced that it has received CNY 100 million in funding from Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd., Lapam Capital, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and other investors
CI
King-Friend Biochemical Wins FDA Nod to Market Cancer Treatment in US
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603707 Stock
  4. News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.